5 aminosalicylic acid

5-Aminosalicylic Acid (5-ASA) is a specific PPARγ agonist and also inhibits P21-activated kinase 1(PAK1) and NF-Κb. 5-Aminosalicylic Acid has anti-cancer and anti-inflammatory activities. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).

N-acetyl-5-Aminosalicylic Acid (N-Acetyl mesalazine) is the major metabolite of mesalazine.

5-Aminosalicylic acid-D3 is the deuterated form of 5-Aminosalicylic Acid. 5-Aminosalicylic acid (T0646) (Mesalamine) functions as a specific PPARγ agonist and also inhibits both p21-activated kinase 1 (PAK1) and NF-κB.

5-Aminosalicylic acid-D3 disodium isodium is a deuterium-labeled variant of 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) functions as a specific PPARγ agonist, and it also inhibits p21-activated kinase 1 (PAK1) and NF-κB. Additionally, it acts to suppress the activity of osteopontin (OPN).

5-Aminosalicylic acid-13C6 is the 13C-labeled form of 5-Aminosalicylic Acid. This compound, also known as 5-Aminosalicylic acid (T0646) (Mesalamine), acts as a specific agonist for PPARγ and inhibits p21-activated kinase 1 (PAK1) as well as NF-κB.

5-Aminosalicylic acid (Standard) is the standard substance of 5-Aminosalicylic acid, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. 5-Aminosalicylic Acid (5-ASA) is a specific PPARγ agonist and also inhibits P21-activated kinase 1(PAK1) and NF-Κb. 5-Aminosalicylic Acid has anti-cancer and anti-inflammatory activities. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).

N-Acetyl-5-Aminosalicylic Acid-[13C6] (Standard) is a reference standard of N-Acetyl-5-Aminosalicylic Acid-[13C6] intended for quantitative analysis, quality control, and related biochemical research applications.

Olsalazine disodium (Dipentum) is bioconverted to 5-aminosalicylic acid (5-ASA) in the colon and has anti-inflammatory activity in ulcerative colitis.

Balsalazide sodium hydrate (Balsalazide disodium) is an anti-inflammatory compound used in the treatment of Inflammatory Bowel Disease.Balsalazide sodium hydrate is a new 5-aminosalicylic acid (5-ASA) containing prodrug. High dose Balsalazide sodium hydrate(3.0 g twice daily) was superior in maintaining remission in patients with ulcerative colitis compared with a low dose (1.5 g twice daily) or a standard dose of mesalazine (0.5 g three times daily). All three treatments were safe and well tolerated [1]. Balsalazide sodium hydrate is approved for the treatment of mild-to-moderate active UC. It is efficacious for the induction of remission in mild to moderate UC and has a favorable safety profile, with the added advantages of greater efficacy of remission induction and rapidity of onset [2].

Olsalazine-13C6 is intended for use as an internal standard for the quantification of olsalazine by GC- or LC-MS. Olsalazine (T20615) is an orally bioavailable prodrug form of the anti-inflammatory agent 5-aminosalicylic acid that is cleaved by bacterial azo reductases in the gut to generate active 5-ASA.1

Mesalamine impurity P is an impurity of Mesalamine. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB [1].

Mesalamine-D3 is a deuterated compound of Mesalamine. Mesalamine (T0646) has a CAS number of 89-57-6. Mesalamine (T0646) is an anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE.

Benzalazine is an azo derivative of 5-Aminosalicylic Acid, used in studies related to ulcerative colitis and Crohn's disease. The metabolite of Benzalazine, 5-Aminosalicylic Acid, is primarily excreted in the feces.